Novo Nordisk results show GLP-1s are job 1. Can its crucial Ozempic launch deliver?
admin 2nd May 2018 Uncategorised 0After Eli Lilly reported Street-beating diabetes sales while Sanofi’s suffered, all eyes were turned to Novo Nordisk. And it’s good news, more or less, for the Danish company, thanks to its GLP-1 franchise, which made up for ongoing insulin trouble. But now, the Ozempic launch has to shine.
More: Novo Nordisk results show GLP-1s are job 1. Can its crucial Ozempic launch deliver?
Source: fierce